Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
AssigneeGalderma S.A.
InventorsFeriel HACINI-RACHINEL, Emmanuel VIAL, André JOMARD
Life of this patent
Estimating the term…
Abstract
A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier.
Claims18
A method of treating atopic dermatitis, the method comprising topically applying a pharmaceutical composition comprising 0.001% to 5% by weight, relative to the total weight of the composition of a compound of the avermectin family or a compound of the milbemycin family in a pharmaceutically acceptable carrier.
The method as defined by claim 9, wherein the pharmaceutical composition comprises by weight, relative to the total weight of the composition:
- Ivermectin 1.0,
- Glycerol 4.0,
- Acrylate C10-30 alkyl acrylate 0.2,
- Methyl para-hydroxybenzoate 0.2,
- Disodium EDTA 0.05,
- Citric acid monohydrate 0.05,
- Isopropyl palmitate 4.0,
- Cetyl alcohol 3.5,
- Stearyl alcohol 2.5,
- Oleyl alcohol 2.0,
- Ceteareth-20 3.0,
- Sorbitan monostearate 2.0,
- Dimethicone 200 20 cs 0.5,
- Propyl para-hydroxybenzoate 0.1,
- Propylene glycol 2.0,
- Phenoxyethanol 1.0,
- 10% sodium hydroxide qs pH, and
- water qs 100,
- as % by weight relative to the total weight of the composition.
A method for treating atopic dermatitis, the method comprising:
- topically applying to the skin of a subject in need thereof a pharmaceutical composition comprising 0.001% to 5% by weight, relative to the total weight of the composition, of a compound of the avermectin family selected from the group consisting of ivermectin, avermectin, abamectin, doramectin, eprinomectin, selamectin, aversectin B, aversectin AB, aversectin C, emamectin B1a, and emamectin B1b.
A method for treating atopic dermatitis, the method comprising:
- topically applying to the skin of a subject in need thereof a pharmaceutical composition comprising 0.001% to 5% by weight, relative to the total weight of the composition, of a compound of the milbemycin family selected from the group consisting of lepimectin, milbemectin, milbemycin oxime, moxidectin, 6′-ethyllepimectin, 6′-methyllepimectin, α-nemadectin, β-nemadectin, γ-nemadectin, and δ-nemadectin.
Dependencies are inferred from the claim text.